The rate of lung cancer has gradually increased in recent years, with an average annual increase of 15%. Afatinib (AFT) plays a key role in preventing non-small cell lung carcinoma (NSCLC) growth and spread. To increase the efficiency of drug loading and NSCLC cell tracking, near infrared-persistent luminescence nanomaterials (NIR PLNs), a silica shell-assisted synthetic route for mono-dispersal, are developed and used in the nanovehicle. After optimizing their physical and chemical properties, the NIR PLNs are able to absorb light energy and emit NIR luminescence for several hours. In this research, NIR PLNs are functionalized for drug-carrying capabilities. Effective accumulation of target drugs, such as AFT, using PLN nanomaterials can lead to unique anticancer therapeutic benefits (AFT-PLN). To minimize side effects and increase drug accumulation, nanomaterials with targeting abilities are used instead of simple drugs to inhibit the growth of tumor cells. Thus, the specific targeting aptamer, MAGE-A3 (MAp) is identified, and the PLN to increase its targeting ability (AFT-PLN@MAp) accordingly modified. The advancement of nanoscale techniques in the field of lung cancer is urgently needed; this research presents a plausible diagnostic strategy and a novel method for therapeutic administration.

中文翻译：

---

下一代癌症特异性混合治疗纳米材料：MAGE-A3 NIR 持久发光纳米颗粒与阿法替尼缀合，用于原位抑制肺腺癌生长和转移。


近年来，肺癌发病率逐渐上升，年均增加15%。阿法替尼 (AFT) 在预防非小细胞肺癌 (NSCLC) 生长和扩散方面发挥着关键作用。为了提高药物装载和非小细胞肺癌细胞追踪的效率，近红外持久发光纳米材料（NIR PLN）是一种二氧化硅壳辅助的单分散合成路线，被开发并用于纳米车辆。在优化其物理和化学特性后，NIR PLN 能够吸收光能并发出近红外光数小时。在这项研究中，NIR PLN 被功能化以实现药物携带能力。使用 PLN 纳米材料有效积累 AFT 等靶标药物可带来独特的抗癌治疗效果 (AFT-PLN)。为了最大限度地减少副作用并增加药物积累，使用具有靶向能力的纳米材料代替简单的药物来抑制肿瘤细胞的生长。因此，鉴定了特异性靶向适体MAGE-A3 (MAp)，并相应地修改了PLN以增加其靶向能力(AFT-PLN@MAp)。肺癌领域迫切需要纳米技术的进步；这项研究提出了一种合理的诊断策略和一种新的治疗管理方法。